Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Jul 28, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to assess prostate cancer using a special type of MRI called Restriction Spectrum Imaging (RSI). The study aims to understand how effective this imaging technique is in evaluating prostate cancer in men who have already been diagnosed with the disease. It will involve 40 male participants, all of whom will undergo two MRI scans within a month.

To participate in this study, men need to be at least 18 years old and have a confirmed diagnosis of prostate cancer. They should also be in good health and scheduled for a standard prostate surgery, which allows researchers to compare the MRI results with actual tissue samples after surgery. Participants will need to agree to follow the study procedures and sign a consent form. It's important to note that men who have received certain treatments for prostate cancer before or have specific health issues may not be eligible. Overall, those who join the trial will contribute to important research that could improve prostate cancer diagnosis and treatment in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male, aged ≥18 years, with histologically confirmed adenocarcinoma of the prostate
• • Has already undergone prostate MRI and/or scheduled to undergo clinically indicated radical prostatectomy (to permit whole-mount histopathology correlation).
• • Intended treatment and follow-up according to standard of care for prostate cancer
• • In good general health as evidenced by medical history and ECOG performance status 0-2
• • Provision of signed and dated informed consent form
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• Exclusion Criteria:
• • Prior treatment for prostate cancer (cryotherapy, high frequency focused ultrasound, prostatectomy)
• • Hip prosthesis
• • Contraindication to MRI, per institutional requirements
• • Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.